Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Huntington's Disease
- Main trialPhase 1
- “This is a first-in-human, multi-center trial studying the effects of SRP-1005 in participants with Huntington's disease (HD).”In the company’s words, NCT07536061 on ClinicalTrials.gov
Other drugs for Huntington's Disease
- SKY-0515Skyhawk Therapeutics, Inc. · Phase 2/3
- ValbenazineNeurocrine Biosciences · Phase 3
- PridopidinePrilenia · Phase 3
- VotoplamNovartis · Phase 3
- VO659Vico Therapeutics B. V. · Phase 1/2
- ER2001ExoRNA Bioscience · Phase 1/2
Coming up1
- 30 Nov 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 30 Nov 2027 | A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026